SPECIAL NOTICE
99 -- Neuroregenerative and Neuroprotective Effects of Retinoic Acid
- Notice Date
- 2/1/2010
- Notice Type
- Special Notice
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- National Institutes of HealthNational Institute on Drug AbuseBethesdaMD20892-7511
- ZIP Code
- 20892-7511
- E-Mail Address
-
LINDSAY, CAROL A
(clindsay@intra.nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse (NIDA), Intramural Research Program (IRP) intends to solicit, negotiate and award a purchase order on a noncompetitive basis with Dr. Jonathan Miller, University Hospital, Case Medical Center, Director, Functional and Restorative Neurosurgery, Assistant Professor of Neurological Surgery, 11100 Euclid Avenue, HAN 5042, Cleveland, Ohio 44106. The National Institutes on Drug Abuse (NIDA), Division of Intramural Research in Baltimore, Maryland requires specialized skills, expertise, facilities and equipment to be able to do the very specific research needed. The type of studies being performed, neuroregenerative and neuroprotective effects of retinoic acid, require very specific types of equipments and techniques in order to provide results that are consistent with NIDA/IRP portions of this program. Dr. Jonathan Miller ran successful experiments using these technologies and thus matches the current requirement of NIDA/IRP using the same techniques for these experiments which will now provide a translational component to this work. Dr. Miller's labs are currently set up with the highly specialized equipment required to perform the experiments required by NIDA/ IRP to further test this research. Three different studies will be done to examine the neuroregenerative effect of retinoic acid. The lab will examine if intranasal RA administration can improve motor function in stroke animals. Examination of RA treatment to increase co-localization of BrdU and NeuN, Map2, GFAP or Nestin in the lesioned cortex and SVZ in stroke animals will also be conducted. Also, examination as to what extent RA induces behavioral recovery, neuroregeneration, and BMP7 expression in the BMP7 -/+ vs. WT animals will also be performed. The acquisition is being conducted under simplified acquisition FAR 13 and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing synopsis number NIHDA2010148 may be submitted to the NIDA, IRP, 251 Bayview Boulevard, Suite 200, BRC Bldg., Rm 04A326, Baltimore, MD 21224, ATTN: Carol Lindsay
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/cb1fbeda930d8936eb2f2f6e381aaaac)
- Record
- SN02054813-W 20100203/100201235216-cb1fbeda930d8936eb2f2f6e381aaaac (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |